FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer

FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer

ReachMD Healthcare Image
RestartResume

    FDA medical oncologists discuss the Sept 14, 2017, approval of MVASI, the first biosimilar approved in the US for the treatment of cancer.

    • Overview

      Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the recent approval of bevacizumab-awwb, a biosimilar to US-licensed Avastin, marketed as MVASI. MVASI is the first biosimilar approved in the US for the treatment of cancer.

      Released on December 21, 2017

    Facebook Comments

    Register

    We’re glad to see you’re enjoying Prova Education…
    but how about a more personalized experience?

    Register for free